NETLIST Loses Three Federal Circuit Appeals Against Micron on Same Day
The Federal Circuit affirmed PTAB rulings invalidating claims of five Netlist memory patents challenged by Micron, including one precedential decision.
Latest
POLESTAR Posts $842M Half-Year Loss as Revenue Slips 4.4%
The EV maker cut its net loss by 29% in H1 2026, but adjusted EBITDA worsened to a loss of $521 million while deliveries were roughly flat.
CAMPBELL'S Cuts Dividend 36% and Guides FY27 EPS Down as Much as 24%
Q4 adjusted EPS fell 37% to $0.39, the quarterly payout drops to $0.25, and Campbell's targets $500 million in cost savings by fiscal 2030.
CIENA Revenue Jumps 37% to $1.67B as AI Drives Optical Demand
Ciena posted record fiscal Q3 revenue of $1.67 billion and adjusted EPS of $2.11, and raised its full-year revenue outlook to $6.42 billion.
APOGEE THERAPEUTICS Buyout Closes as Shares Head for Delisting
An 8-K filing shows Apogee Therapeutics has completed a change-of-control transaction, replaced its board and recapitalized to just 1,000 shares.
ELASTIC Founder Shay Banon Sells $44.5M in Shares Over Three Days
Elastic's CTO and co-founder disposed of about 476,000 ordinary shares between August 31 and September 2, cutting his stake to roughly 1.58 million shares.
Aura Minerals Director Sells $10.4 Million of Shares in Open Market
A Form 4 shows director Bruno Sousa Mauad sold 127,500 Aura Minerals shares at $81.20 apiece on Aug. 31, cutting his stake by more than 40%.
CrowdStrike Co-Founder Kurtz and Director Gandhi Sell $8.8M in Stock
Two CrowdStrike insiders sold a combined 40,000 Class A shares on Aug. 31 and Sept. 1 at prices between roughly $213 and $234.
NESR CEO Sherif Foda Sells $3.5M in Stock, Gifts 675,000 Shares
National Energy Services Reunited's chief executive sold 100,000 ordinary shares at $35.00 and transferred another 675,000 shares as a gift.
FDA Approves Rasonque, First RAS Inhibitor for Metastatic Pancreatic Cancer
The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.
FDA Approves Lisraya, First Oral Drug for Dermatomyositis in Adults
The FDA has cleared Lisraya (brepocitinib) tablets, the first oral therapy specifically indicated for adults with dermatomyositis.
FDA Approves Mimrylo (Rusfertide), First Hepcidin Mimetic for Polycythemia Vera
The FDA has cleared Mimrylo (rusfertide) for adults with polycythemia vera, calling it the first drug of its kind for the rare blood disorder.
ABT
FDA Authorizes First Dual Glucose and Ketone Wearable, Abbott's Libre Duo
The FDA cleared the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people with diabetes aged 2 and older.
DH
Advent Offers $1.02 a Share to Take Definitive Healthcare (DH) Private
A special committee of independent directors confirmed a non-binding all-cash proposal from Advent International for all shares it does not already own.
ABI
Abcourt Closes US$10M Debenture Upsize With Glencore, Repays Nebari Loan
Abcourt Mines lifted its Glencore senior secured debenture to US$40 million, drew US$19.875 million and repaid a US$12 million Nebari credit facility.
BRLS
Borealis Foods Gets Nasdaq Deficiency Notice Over Late Q2 10-Q
Borealis Foods says a review of the accounting treatment of its Conversion Agreement delayed its second-quarter report, triggering a Nasdaq compliance notice.
Clinical
Spectrum Pharmaceuticals Suspends Phase 3 Poziotinib Trial in HER2 NSCLC
The registry entry for the poziotinib study in HER2 exon 20-mutated lung cancer now reads SUSPENDED, with no patients enrolled and a redesign under discussion with the FDA.
HRMY
Harmony Biosciences Completes Phase 3 Cannabidiol Trial in Fragile X
The registry entry for Harmony's Phase 3 study of cannabidiol in Fragile X syndrome now shows a status of COMPLETED, updated 1 September 2026.
Clinical
PDS Biotechnology Terminates Phase 3 Trial of PDS0101 in HPV16+ Head and Neck Cancer
PDS Biotechnology has terminated its Phase 3 study of PDS0101 plus pembrolizumab, citing financial constraints rather than safety concerns.
VRT
Vertiv Signs $1.45 Billion Merger Deal for Utility Innovation Holdings
Vertiv Corporation agreed to acquire Utility Innovation Holdings via merger, with a base purchase price of $1.45 billion plus an earnout, per an 8-K filing.
INCY
Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed
The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.